BVF Inc. IL Grows Holdings in Molecular Partners AG (NASDAQ:MOLN)

BVF Inc. IL lifted its position in shares of Molecular Partners AG (NASDAQ:MOLN - Free Report) by 205.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,353,968 shares of the company's stock after buying an additional 910,747 shares during the quarter. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent reporting period.

Molecular Partners Trading Up 0.6 %

MOLN stock traded up $0.02 during mid-day trading on Wednesday, reaching $4.10. The company's stock had a trading volume of 2,525 shares, compared to its average volume of 20,999. Molecular Partners AG has a 12 month low of $3.36 and a 12 month high of $12.70. The business's 50 day moving average price is $4.06 and its 200 day moving average price is $4.96. The company has a market cap of $165.70 million, a price-to-earnings ratio of -1.91 and a beta of 1.15.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%. As a group, equities analysts expect that Molecular Partners AG will post -1.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Lifesci Capital assumed coverage on shares of Molecular Partners in a research report on Tuesday, March 11th. They set an "outperform" rating and a $12.00 price target on the stock.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.